移植片対宿主病(GVHD)治療薬のアメリカ市場:市場インサイト、疫学分析、市場予測

DelveInsightが発行した調査報告書(DLVE704016)
◆英語タイトル:Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- United States
◆商品コード:DLVE704016
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年1月
◆ページ数:60
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:米国
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,450 ⇒換算¥276,850見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,900 ⇒換算¥553,700見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD7,350 ⇒換算¥830,550見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s “Graft versus Host Disease (GVHD) – Market Insights, Epidemiology and Market Forecast-2023-United States” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes global market size of the Graft Versus Host Disease (GVHD) for the United States.GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.92% from 2013-2023 and reach up to 27,114 cases in the year 2023.
The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 1.00% and 4.14%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 1.00% and 4.14%, respectively, by the end of the year 2023.
The market size of GVHD mainly comprises of the off-label biologics. Many companies are working on the development of targeted therapy and in the near future, these drugs may create an impact on the overall market size of GVHD. DelveInsight’s estimates suggest that the forecasted market size of Graft Versus Host Disease (GVHD) in United States shall increase at a CAGR of 4.62% from 2013 to 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) ( which also includes the cases of first transplants along with the total transplants)
- The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for United States from 2013-2023.
- The Report also includes historical and forecasted Market size of GVHD for United States from 2013 to 2023.
- It provides the information of available marketed therapies, including off-label biologics, patent and exclusivity details.
- The report also focuses on the details of pipeline drugs in the pivotal stage of development including their SWOT Analysis and expected launch date, which shall help to predict the impact of those drugs on the market size in the near future.

【レポートの目次】

Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GVHD
Chronic GVHD
Grades of GVHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Assumptions and Rationale
Treatment Algorithm
Guidelines and Recommendations for Treatment of GVHD in United States
Current Unmet Needs of Graft Versus Host Disease (GVHD)
Marketed Drugs
Temcell HS
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Temcell HS
Side effects of Temcell HS
SWOT Analysis of Temcell HS
Remicade
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Remicade
Side effects of Remicade
SWOT Analysis
Lemtrada
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Lemtrada
Adverse reactions of Lemtrada
SWOT Analysis
Velcade
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Velcade
Side effects of Velcade
SWOT Analysis
Gleevec
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Gleevec
Adverse reactions of Gleevec
SWOT Analysis
Rapamune
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Rapamune
Adverse reactions of Rapamune
SWOT Analysis
Simulect
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Simulect
Side effects of Simulect
SWOT Analysis
Enbrel
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Enbrel
Side effects of Enbrel
SWOT Analysis
Orencia
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Orencia
Side effects of Orencia
SWOT Analysis
Nulojix
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Nulojix
Side effects of Orencia
SWOT Analysis
Emerging Drugs Analysis
Emerging Drugs
Begelomab
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Budesonide
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Methoxsalen
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Market Size
United States
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Table 2: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 3: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 4: GVHD Prophylaxis regimen for Myeloablative conditioning
Table 5: GVHD Prophylaxis regimen for Reduced intensity conditioning
Table 6: Begelomab, Clinical Trials by Zone, 2017
Table 7: Clinical Trials by Recruitment status, 2017
Table 8: Budesonide, Clinical Trials by Zone, 2017
Table 9: Clinical Trials by Recruitment status, 2017
Table 10: Methoxsalen, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Recruitment status, 2017
Table 12: United States market size of GVHD in USD, Million (2013-2023)
Table 13: United States market size of GVHD by treatment type in USD, Million (2013-2023)


Figure 1: Pathophysiology of GVHD
Figure 2: Risk Factors for GVHD
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Figure 4: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Figure 5: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Figure 6: Treatment Algorithm of GVHD
Figure 7: Begelomab, Clinical Trials by Zone (%), 2017
Figure 8: Begelomab, Clinical Trials by Recruitment status (%), 2017
Figure 9: Budesonide, Clinical Trials by Zone (%), 2017
Figure 10: Budesonide, Clinical Trials by Recruitment status (%), 2017
Figure 11: Methoxsalen, Clinical Trials by Zone (%), 2017
Figure 12: Methoxsalen, Clinical Trials by Recruitment status (%), 2017
Figure 13: Spain market size of GVHD in USD, Million (2013-2023)
Figure 14: United States market size of GVHD in USD, Million (2013-2023)
Figure 15: United States market size of GVHD by treatment type in USD, Million (2013-2023)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 移植片対宿主病(GVHD)治療薬のアメリカ市場:市場インサイト、疫学分析、市場予測(Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- United States)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆